Evidence map›Paper›PMID 41835051›Full record

ReviewAdvanced pharmaceutical bulletin2025

Hydrogel Micro/Nanostructures for the Delivery of Oncolytic Viruses: Overcoming Limitations and Improving Efficacy.

Chou-Yi Hsu, Saade Abdalkareem Jasim, Jasur Alimdjanovich Rizaev, Tina Saeed Basunduwah, Vikrant Abbot, Mamata Chahar, Mohammed Asiri, Abbas Fadhel Ali, Alexey Yumashev, Ahmed Hussein Zwamel

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced pharmaceutical bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chou-Yi HsuThunderbird School of Global Management, Arizona State University Tempe Campus, Phoenix, Arizona 85004, USA.ORCID https://orcid.org/0000-0001-7105-1161
Saade Abdalkareem JasimMedical Laboratory Techniques Department, College of Health and Medical Techniques, University of Al-Maarif, Anbar, Iraq.ORCID https://orcid.org/0009-0009-0821-5843
Jasur Alimdjanovich RizaevDepartment of Public Health and Healthcare Management, Rector, Samarkand State Medical University, 18, Amir Temur Street, Samarkand, Uzbekistan.
Tina Saeed BasunduwahDepartment of Medical Student, University of Albatterjee College, Jeddah, Saudi Arabia.ORCID https://orcid.org/0009-0000-7386-051X
Vikrant AbbotChandigarh Pharmacy College, Chandigarh Group of Colleges, Jhanjeri, Mohali 140307, Punjab, India.
Mamata ChaharDepartment of Chemistry, NIMS University, Jaipur, India.
Mohammed AsiriDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Abbas Fadhel AliDepartment of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq.
Alexey YumashevDepartment of Prosthetic Dentistry, First Moscow State Medical University, Russia.ORCID https://orcid.org/0000-0002-5184-0195
Ahmed Hussein ZwamelMedical Laboratory Technique College, the Islamic University, Najaf, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic viruses (OVs) have attracted accumulating attention in cancer therapy owing to their ability to replicate in and kill tumor cells, resulting in the stimulation of immune responses for eradicating residual and distant malignant cells. Despite milestone achievements in the development of OVs, which led to the U.S. Food and Drug Administration (FDA) approval of talimogene laherparepvec (T-VEC) in 2015 against melanoma, there are some hurdles limiting their translation from the bench to the clinic, such as non-specific localization, host immune response against OVs and their clearance, and low efficiency as a monotherapy. Delivery of OVs with nano-biomaterials is a promising approach to address the drawback of oncolytic virotherapy. Hydrogels, with their tunable characteristics and versatile properties, offer a promising platform for the controlled release, precise delivery, and therapeutic enhancement of OVs in combination with other therapeutic agents in the treatment of cancers. This review aims to provide a deep insight into the types and development of OVs and their application in clinical trials and then will discuss the characteristics of hydrogels and how they improve the therapeutic efficacy of OVs.

Indexed as

CancerHydrogelImmune responseOncolytic virotherapyOncolytic viruses

Identifiers

PMID41835051
PMCPMC12980211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.